The pathogenesis of Alzheimer’s disease (AD) is complicated and involves multiple contributing factors. Mounting evidence supports the concept that AD is an age-related metabolic neurodegenerative disease mediated in part by brain insulin resistance, and sharing similar metabolic dysfunctions and brain pathological characteristics that occur in type 2 diabetes mellitus (T2DM) and other insulin resistance disorders. Brain insulin signal pathway is a major regulator of branched-chain amino acid (BCAA) metabolism. In the past several years, impaired BCAA metabolism has been described in several insulin resistant states such as obesity, T2DM and cardiovascular disease. Disrupted BCAA metabolism leading to elevation in circulating BCAAs and related metabolites is an early metabolic phenotype of insulin resistance and correlated with future onset of T2DM. Brain is a major site for BCAA metabolism. BCAAs play pivotal roles in normal brain function, especially in signal transduction, nitrogen homeostasis, and neurotransmitter cycling. Evidence from animal models and patients support the involvement of BCAA dysmetabolism in neurodegenerative diseases including Huntington’s disease, Parkinson’s disease, and maple syrup urine disease. More recently, growing studies have revealed altered BCAA metabolism in AD, but the relationship between them is poorly understood. This review is focused on the recent findings regarding BCAA metabolism and its role in AD. Moreover, we will explore how impaired BCAA metabolism influences brain function and participates in the pathogenesis of AD.
Alzheimer’s Association (2020) 2020 Alzheimer’s disease facts and figures. Alzheimers Dement16, 391–460.
3.
(2022) 2022 Alzheimer’s disease facts and figures. Alzheimers Dement18, 700–789.
4.
NeergaardJS, DragsbækK, ChristiansenC, NielsenHB, BrixS, KarsdalMA, HenriksenK (2017) Metabolic syndrome, insulinresistance, and cognitive dysfunction: Does your metabolic profileaffect your brain?Diabetes66, 1957–1963.
5.
KshirsagarV, ThingoreC, JuvekarA (2021) Insulin resistance: A connecting link between Alzheimer’s disease and metabolic disorder. Metab Brain Dis36, 67–83.
6.
YooHS, ShanmugalingamU, SmithPD (2022) Potential roles of branched-chain amino acids in neurodegeneration. Nutrition103-104, 111762.
StoeckelLE, ArvanitakisZ, GandyS, SmallD, KahnCR, Pascual-LeoneA, PawlykA, SherwinR, SmithP (2016) Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction. F1000Res5, 353.
9.
Diniz PereiraJ, Gomes FragaV, Morais SantosAL, CarvalhoMDG, CaramelliP, Braga GomesK (2021) Alzheimer’s disease and type 2 diabetes mellitus: A systematic review of proteomic studies. J Neurochem156, 753–776.
10.
EbrahimpourS, ZakeriM, EsmaeiliA (2020) Crosstalk between obesity, diabetes, and alzheimer’s disease: Introducing quercetin as an effective triple herbal medicine. Ageing Res Rev62, 101095.
11.
BiesselsGJ, StrachanMW, VisserenFL, KappelleLJ, WhitmerRA (2014) Dementia and cognitive decline in type 2 diabetes andprediabetic stages: Towards targeted interventions. Lancet Diabetes Endocrinol2, 246–255.
TakedaS, SatoN, Uchio-YamadaK, SawadaK, KuniedaT, TakeuchiD, KurinamiH, ShinoharaM, RakugiH, MorishitaR (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A107, 7036–7041.
14.
BhatNR, ThirumangalakudiL (2013) Increased tau phosphorylation and impaired brain insulin/IGF signaling in mice fed a high fat/high cholesterol diet. J Alzheimers Dis36, 781–789.
KimB, BackusC, OhS, HayesJM, FeldmanEL (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology150, 5294–5301.
17.
WrightenSA, PiroliGG, GrilloCA, ReaganLP (2009) A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim Biophys Acta1792, 444–453
18.
SchubertM, GautamD, SurjoD, UekiK, BaudlerS, SchubertD, KondoT, AlberJ, GalldiksN, KustermannE, ArndtS, JacobsAH, KroneW, KahnCR, BruningJC (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A101, 3100–3105.
19.
KavanaghK, DaySM, PaitMC, MortizWR, NewgardCB, IlkayevaO, McClainDA, MacauleySL (2019) Type-2-diabetes alters CSF but not plasma metabolomic and AD risk profiles in vervet monkeys. Front Neurosci13, 843.
20.
MorrisJK, PiccoloBD, ShankarK, ThyfaultJP, AdamsSH (2018) The serum metabolomics signature of type 2 diabetes is obscured in Alzheimer’s disease. Am J Physiol Endocrinol Metab314, E584–E596.
21.
KullmannS, HeniM, HallschmidM, FritscheA, PreisslH, HäringHU (2016) brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol Rev96, 1169–1209.
22.
FolchJ, OlloquequiJ, EttchetoM, BusquetsO, Sanchez-LopezE, CanoA, Espinosa-JimenezT, GarciaML, Beas-ZarateC, CasadesusG, BulloM, AuladellC, CaminsA (2019) The involvement of peripheral and brain insulin resistance in late onset Alzheimer’s dementia. Front Aging Neurosci11, 236.
23.
AgrawalR, RenoCM, SharmaS, ChristensenC, HuangY, FisherSJ (2021) Insulin action in the brain regulates both central and peripheral functions. Am J Physiol Endocrinol Metab321, E156–E163.
24.
AkhtarA, SahSP (2020) Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer’s disease. Neurochem Int135, 104707.
25.
de la MonteSM, WandsJR (2005) Review of insulin and insulin-likegrowth factor expression, signaling, and malfunction in the centralnervous system: Relevance to Alzheimer’s disease. J Alzheimers Dis7, 45–61.
26.
GrilloCA, PiroliGG, HendryRM, ReaganLP (2009) Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res1296, 35–45.
27.
Arrieta-CruzI, Gutiérrez-JuárezR (2016) The role ofinsulin resistance and glucose metabolism dysregulation in thedevelopment of Alzheimer’s disease. Rev Invest Clin68, 53–58.
28.
SedzikowskaA, SzablewskiL (2021) Insulin and insulin resistance in Alzheimer’s disease. Int J Mol Sci22, 9987.
29.
FerreiraST (2021) Brain insulin, insulin-like growth factor 1 and glucagon-like peptide 1 signalling in Alzheimer’s disease. J Neuroendocrinol33, e12959.
30.
KellarD, CraftS (2020) Brain insulin resistance in Alzheimer’s disease and related disorders: Mechanisms and therapeutic approaches. Lancet Neurol19, 758–766.
31.
de la MonteSM (2014) Type 3 diabetes is sporadic Alzheimer’s disease: Mini-review. Eur Neuropsychopharmacol24, 1954–1960.
LeclercM, BourassaP, TremblayC, CaronV, SugereC, EmondV, BennettDA, CalonF (2023) Cerebrovascular insulin receptors are defective in Alzheimer’s disease. Brain146, 75–90.
34.
KulasJA, WeigelTK, FerrisHA (2020) Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer’s disease. Drug Dev Res81, 194–205.
35.
de la MonteSM (2017) Insulin resistance and neurodegeneration: Progress towards the development of new therapeutics for Alzheimer’s disease. Drugs77, 47–65.
36.
YangY, MaD, WangY, JiangT, HuS, ZhangM, YuX, GongCX (2013) Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. J Alzheimers Dis33, 329–338.
SotoM, CaiW, KonishiM, KahnCR (2019) Insulin signaling in the hippocampus and amygdala regulates metabolism and neurobehavior. Proc Natl Acad Sci U S A116, 6379–6384.
39.
RuizHH, ChiT, ShinAC, LindtnerC, HsiehW, EhrlichM, GandyS, BuettnerC (2016) Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer’s disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels. Alzheimers Dement12, 851–861.
40.
JanoutováJ, MachaczkaO, ZatloukalováA, JanoutV (2022) IsAlzheimer’s disease a type 3 diabetes? A review. Cent Eur J Public Health30, 139–143.
41.
SteenE, TerryBM, RiveraEJ, CannonJL, NeelyTR, TavaresR, XuXJ, WandsJR, de la MonteSM (2005) Impaired insulin and insulin-likegrowth factor expression and signaling mechanisms in Alzheimer’sdisease–is this type 3 diabetes?J Alzheimers Dis7, 63–80.
42.
MichailidisM, MoraitouD, TataDA, KalinderiK, PapamitsouT, PapaliagkasV (2022) Alzheimer’s disease as type 3 diabetes: Common pathophysiological mechanisms between Alzheimer’s disease and type 2 diabetes. Int J Mol Sci23, 2687.
LaymanDK (2003) The role of leucine in weight loss diets and glucose homeostasis. J Nutr. 133, 261S–267S.
45.
BaquetA, LavoinneA, HueL (1991) Comparison of the effects of various amino acids on glycogen synthesis, lipogenesis and ketogenesis in isolated rat hepatocytes. Biochem J273(Pt 1), 57–62.
46.
FeligP, MarlissE, CahillGFJr. (1969) Plasma amino acid levels and insulin secretion in obesity. N Engl J Med281, 811–816.
47.
De BandtJP, CoumoulX, BaroukiR (2022) Branched-chain amino acids and insulin resistance, from protein supply to diet-induced obesity. Nutrients15, 68.
48.
Le CouteurDG, Solon-BietSM, CoggerVC, RibeiroR, de CaboR, RaubenheimerD, CooneyGJ, SimpsonSJ (2020) Branched chain amino acids, aging and age-related health. Ageing Res Rev64, 101198.
NewgardCB, AnJ, BainJR, MuehlbauerMJ, StevensRD, LienLF, HaqqAM, ShahSH, ArlottoM, SlentzCA, RochonJ, GallupD, IlkayevaO, WennerBR, YancyWSJr., EisensonH, MusanteG, SurwitRS, MillingtonDS, ButlerMD, SvetkeyLP (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab9, 311–326.
51.
WangTJ, LarsonMG, VasanRS, ChengS, RheeEP, McCabeE, LewisGD, FoxCS, JacquesPF, FernandezC, O’DonnellCJ, CarrSA, MoothaVK, FlorezJC, SouzaA, MelanderO, ClishCB, GersztenRE (2011) Metabolite profiles and the risk of developing diabetes. Nat Med17, 448–453.
52.
WürtzP, SoininenP, KangasAJ, RönnemaaT, LehtimäkiT, KähönenM, ViikariJS, RaitakariOT, Ala-KorpelaM (2013) Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care36, 648–655.
53.
FiehnO, GarveyWT, NewmanJW, LokKH, HoppelCL, AdamsSH (2010) Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS One5, e15234.
54.
BadoudF, LamKP, DiBattistaA, PerreaultM, ZulyniakMA, CattrysseB, StephensonS, Britz-McKibbinP, MutchDM (2014) Serum and adipose tissue amino acid homeostasis in the metabolically healthy obese. J Proteome Res13, 3455–3466.
55.
McCormackSE, ShahamO, McCarthyMA, DeikAA, WangTJ, GersztenRE, ClishCB, MoothaVK, GrinspoonSK, FleischmanA (2013) Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes8, 52–61.
56.
RamzanI, ArdavaniA, VanweertF, MellettA, AthertonPJ, IdrisI (2022) The association between circulating branched chain amino acids and the temporal risk of developing type 2 diabetes mellitus: A systematic review & meta-analysis. Nutrients14, 4411.
57.
TillinT, HughesAD, WangQ, WurtzP, Ala-KorpelaM, SattarN, ForouhiNG, GodslandIF, EastwoodSV, McKeiguePM, ChaturvediN (2015) Diabetes risk and amino acid profiles: Cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study. Diabetologia58, 968–979.
58.
Jachthuber TrubC, BalikciogluM, FreemarkM, BainJ, MuehlbauerM, IlkayevaO, WhitePJ, ArmstrongS, OstbyeT, GrambowS, Gumus BalikciogluP (2021) Impact of lifestyle Intervention on branched-chain amino acid catabolism and insulin sensitivity in adolescents with obesity. Endocrinol Diabetes Metab4, e00250.
59.
Solon-BietSM, GriffithsL, FoshS, Le CouteurDG, SimpsonSJ, SeniorAM (2022) Meta-analysis links dietary branched-chain amino acids to metabolic health in rodents. BMC Biol20, 19.
LiX, WangX, LiuR, MaY, GuoH, HaoL, YaoP, LiuL, SunX, HeK, CaoW, YangX (2013) Chronic leucine supplementation increases body weight and insulin sensitivity in rats on high-fat diet likely by promoting insulin signaling in insulin-target tissues. Mol Nutr Food Res57, 1067–1079.
65.
LiuR, LiH, FanW, JinQ, ChaoT, WuY, HuangJ, HaoL, YangX (2017) Leucine supplementation differently modulates branched-chain amino acid catabolism, mitochondrial function and metabolic profiles at the different stage of insulin resistance in rats on high-fat diet. Nutrients9, 565.
WhitePJ, McGarrahRW, HermanMA, BainJR, ShahSH, NewgardCB (2021) Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street. Mol Metab52, 101261.
68.
HagenfeldtL, ErikssonS, WahrenJ (1980) Influence of leucine on arterial concentrations and regional exchange of amino acids in healthy subjects. Clin Sci (Lond)59, 173–181.
69.
FernstromJD (2013) Large neutral amino acids: Dietary effects on brain neurochemistry and function. Amino Acids45, 419–430.
70.
PardridgeWM (1977) Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain barrier. J Neurochem28, 103–108.
71.
SmithQR, MommaS, AoyagiM, RapoportSI (1987) Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem49, 1651–1658.
72.
YudkoffM (1997) Brain metabolism of branched-chain amino acids. Glia21, 92–98.
73.
SalcedoC, AndersenJV, VintenKT, PinborgLH, WaagepetersenHS, FreudeKK, AldanaBI (2021) Functional metabolic mapping reveals highly active branched-chain amino acid metabolism in human astrocytes, which is impaired in iPSC-derived astrocytes in Alzheimer’s disease. Front Aging Neurosci13, 736580.
74.
BasunH, ForssellLG, AlmkvistO, CowburnRF, EklöfR, WinbladB, WetterbergL (1990) Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer’s disease and healthy control subjects. J Neural Transm Park Dis Dement Sect2, 295–304.
75.
González-DomínguezR, García-BarreraT, Gómez-ArizaJL (2015) Metabolite profiling for the identification of alteredmetabolic pathways in Alzheimer’s disease. J Pharm Biomed Anal107, 75–81.
TynkkynenJ, ChourakiV, van der LeeSJ, HernesniemiJ, YangQ, LiS, BeiserA, LarsonMG, SaaksjarviK, ShipleyMJ, Singh-ManouxA, GersztenRE, WangTJ, HavulinnaAS, WurtzP, FischerK, DemirkanA, IkramMA, AminN, LehtimakiT, KahonenM, PerolaM, MetspaluA, KangasAJ, SoininenP, Ala-KorpelaM, VasanRS, KivimakiM, van DuijnCM, SeshadriS, SalomaaV (2018) Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer’s disease: A prospective study in eight cohorts. Alzheimers Dement14, 723–733.
78.
YangZ, WangJ, ChenJ, LuoM, XieQ, RongY, WuY, CaoZ, LiuY (2022) High-resolution NMR metabolomics of patients with subjective cognitive decline plus: Perturbations in the metabolism of glucose and branched-chain amino acids. Neurobiol Dis171, 105782.
79.
HuddF, ShielA, HarrisM, BowdlerP, McCannB, TsivosD, WearnA, KnightM, KauppinenR, CoulthardE, WhiteP, ConwayME (2019) Novel blood biomarkers that correlate with cognitive performance and hippocampal volumetry: Potential for early diagnosis of Alzheimer’s disease. J Alzheimers Dis67, 931–947.
80.
LiH, YeD, XieW, HuaF, YangY, WuJ, GuA, RenY, MaoK (2018) Defect of branched-chain amino acid metabolism promotes the development of Alzheimer’s disease by targeting the mTOR signaling. Biosci Rep38, BSR20180127.
81.
SiddikMAB, ShinAC (2019) Recent progress on branched-chain amino acids in obesity, diabetes, and beyond. Endocrinol Metab (Seoul)34, 234–246.
82.
PanX, NasaruddinMB, ElliottCT, McGuinnessB, PassmoreAP, KehoePG, HölscherC, McCleanPL, GrahamSF, GreenBD (2016) Alzheimer’s disease-like pathology has transient effects on the brain and blood metabolome. Neurobiol Aging38, 151–163.
83.
LarssonSC, MarkusHS (2017) Branched-chain amino acids and Alzheimer’s disease: A Mendelian randomization analysis. Sci Rep7, 13604.
TournissacM, VandalM, TremblayC, BourassaP, VancasselS, EmondV, GangloffA, CalonF (2018) Dietary intake of branched-chain amino acids in a mouse model of Alzheimer’s disease: Effects on survival, behavior, and neuropathology. Alzheimers Dement (N Y)4, 677–687.
86.
SiddikMAB, MullinsCA, KramerA, ShahH, GannabanRB, Zabet-MoghaddamM, HuebingerRM, HegdeVK, MohanKumarSMJ, MohanKumarPS, ShinAC (2022) Branched-chain amino acids are linked with Alzheimer’s disease-related pathology and cognitive deficits. Cells11, 3523.
87.
SalekRM, XiaJ, InnesA, SweatmanBC, AdalbertR, RandleS, McGowanE, EmsonPC, GriffinJL (2010) A metabolomic study of the CRND8 transgenic mouse model of Alzheimer’s disease. Neurochem Int56, 937–947.
88.
González-DomínguezR, García-BarreraT, VitoricaJ, Gómez-ArizaJL (2015) Metabolomic investigation of systemic manifestations associated with Alzheimer’s disease in the APP/PS1 transgenic mouse model. Mol Biosyst11, 2429–2440.
89.
LynchCJ, AdamsSH (2014) Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol10, 723–736.
90.
YoonMS (2016) The emerging role of branched-chain amino acids in insulin resistance and metabolism. Nutrients8, 405.
SheP, Van HornC, ReidT, HutsonSM, CooneyRN, LynchCJ (2007) Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am J Physiol Endocrinol Metab293, E1552–1563.
HullJ, HindyME, KehoePG, ChalmersK, LoveS, ConwayME (2012) Distribution of the branched chain aminotransferase proteins in the human brain and their role in glutamate regulation. J Neurochem123, 997–1009.
97.
BledsoeRK, DawsonPA, HutsonSM (1997) Cloning of the rat and human mitochondrial branched chain aminotransferases (BCATm). Biochim Biophys Acta1339, 9–13.
98.
ShimomuraY, ObayashiM, MurakamiT, HarrisRA (2001) Regulation of branched-chain amino acid catabolism: Nutritional and hormonal regulation of activity and expression of the branched-chain alpha-keto acid dehydrogenase kinase. Curr Opin Clin Nutr Metab Care4, 419–423.
99.
ZhenH, KitauraY, KadotaY, IshikawaT, KondoY, XuM, MorishitaY, OtaM, ItoT, ShimomuraY (2016) mTORC1 is involved in the regulation of branched-chain amino acid catabolism in mouse heart. FEBS Open Bio6, 43–49.
100.
HutsonSM, CreeTC, HarperAE (1978) Regulation of leucine and alpha-ketoisocaproate metabolism in skeletal muscle. J Biol Chem253, 8126–8133.
101.
ShinnickFL, HarperAE (1976) Branched-chain amino acid oxidation by isolated rat tissue preparations. Biochim Biophys Acta437, 477–486.
102.
SuryawanA, HawesJW, HarrisRA, ShimomuraY, JenkinsAE, HutsonSM (1998) A molecular model of human branched-chain amino acid metabolism. Am J Clin Nutr68, 72–81.
103.
WhitePJ, LapworthAL, AnJ, WangL, McGarrahRW, StevensRD, IlkayevaO, GeorgeT, MuehlbauerMJ, BainJR, TrimmerJK, BrosnanMJ, RolphTP, NewgardCB (2016) Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. Mol Metab5, 538–551.
104.
WhitePJ, McGarrahRW, GrimsrudPA, TsoSC, YangWH, HaldemanJM, Grenier-LaroucheT, AnJ, LapworthAL, AstapovaI, HannouSA, GeorgeT, ArlottoM, OlsonLB, LaiM, ZhangGF, IlkayevaO, HermanMA, WynnRM, ChuangDT, NewgardCB (2018) The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase. Cell Metab27, 1287–1293 e1287.
105.
XuJ, JakherY, Ahrens-NicklasRC (2020) Brain branched-chain amino acids in maple syrup urine disease: Implications for neurological disorders. Int J Mol Sci21, 7490.
106.
García-CazorlaA, OyarzabalA, FortJ, RoblesC, CastejónE, Ruiz-SalaP, BodoyS, MerineroB, Lopez-SalaA, DopazoJ, NunesV, UgarteM, ArtuchR, PalacínM, Rodríguez-PomboP, AlcaideP, NavarreteR, SanzP, Font-LlitjósM, VilasecaMA, OrmaizabalA, PristoupilovaA, AgullóSB (2014) Two novel mutations in the BCKDK (branched-chain keto-acid dehydrogenase kinase) gene are responsible for a neurobehavioral deficit in two pediatric unrelated patients. Hum Mutat35, 470–477.
107.
NovarinoG, El-FishawyP, KayseriliH, MeguidNA, ScottEM, SchrothJ, SilhavyJL, KaraM, KhalilRO, Ben-OmranT, Ercan-SencicekAG, HashishAF, SandersSJ, GuptaAR, HashemHS, MaternD, GabrielS, SweetmanL, RahimiY, HarrisRA, StateMW, GleesonJG (2012) Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science338, 394–397.
AndersenJV, SkotteNH, AldanaBI, NorremolleA, WaagepetersenHS (2019) Enhanced cerebral branched-chain amino acid metabolism in R6/2 mouse model of Huntington’s disease. Cell Mol Life Sci76, 2449–2461.
110.
PerryTL, HansenS, LeskD (1972) Plasma amino acid levels in children of patients with Huntington’s chorea. Neurology22, 68–70.
111.
MochelF, BenaichS, RabierD, DurrA (2011) Validation of plasma branched chain amino acids as biomarkers in Huntington disease. Arch Neurol68, 265–267.
112.
ReilmannR, RolfLH, LangeHW (1995) Decreased plasma alanine and isoleucine in Huntington’s disease. Acta Neurol Scand91, 222–224.
113.
SiddikMAB, MoghaddamMZ, HegdeV, ShinA (2019) Branched-chain amino acid metabolism is impaired in mice and humans with Alzheimer’s disease (OR27-04-19). Curr Dev Nutr3, 684.
114.
OdesseyR, GoldbergAL (1972) Oxidation of leucine by rat skeletal muscle. Am J Physiol223, 1376–1383.
115.
HullJ, Usmari MoraesM, BrookesE, LoveS, ConwayME (2018) Distribution of the branched-chain α-ketoacid dehydrogenase complex E1α subunit and glutamate dehydrogenase in the human brain and their role in neuro-metabolism. Neurochem Int112, 49–58.
116.
HullJ, PatelVB, HutsonSM, ConwayME (2015) New insights into the role of the branched-chain aminotransferase proteins in the human brain. J Neurosci Res93, 987–998.
ShenJ (2013) Modeling the glutamate-glutamine neurotransmitter cycle. Front Neuroenergetics5, 1.
119.
AndersenJV, MarkussenKH, JakobsenE, SchousboeA, WaagepetersenHS, RosenbergPA, AldanaBI (2021) Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration. Neuropharmacology196, 108719.
120.
TaniH, DullaCG, FarzampourZ, Taylor-WeinerA, HuguenardJR, ReimerRJ (2014) A local glutamate-glutamine cycle sustains synaptic excitatory transmitter release. Neuron81, 888–900.
121.
CunnaneSC, TrushinaE, MorlandC, PrigioneA, CasadesusG, AndrewsZB, BealMF, BergersenLH, BrintonRD, de la MonteS, EckertA, HarveyJ, JeggoR, JhamandasJH, KannO, la CourCM, MartinWF, MithieuxG, MoreiraPI, MurphyMP, NaveKA, NurielT, OlietSHR, SaudouF, MattsonMP, SwerdlowRH, MillanMJ (2020) Brain energy rescue: An emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov19, 609–633.
122.
HullJ, PatelV, El HindyM, LeeC, OdeleyeE, HezwaniM, LoveS, KehoeP, ChalmersK, ConwayM (2015) Regional increase in the expression of the BCAT proteins in Alzheimer’s disease bra, Imlications in glutamate toxicity. J Alzheimers Dis45, 891–905.
123.
WangXL, LiCJ, XingY, YangYH, JiaJP (2015) Hypervalinemia and hyperleucine-isoleucinemia caused by mutations in the branched-chain-amino-acid aminotransferase gene. J Inherit Metab Dis38, 855–861.
124.
ZhangS, ZengX, RenM, MaoX, QiaoS (2017) Novel metabolic and physiological functions of branched chain amino acids: A review. J Anim Sci Biotechnol8, 10.
125.
PerluigiM, Di DomenicoF, ButterfieldDA (2015) mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol Dis84, 39–49.
126.
BockaertJ, MarinP (2015) mTOR in brain physiology and pathologies. Physiol Rev95, 1157–1187.
127.
TramutolaA, TriplettJC, Di DomenicoF, NiedowiczDM, MurphyMP, CocciaR, PerluigiM, ButterfieldDA (2015) Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): Analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. J Neurochem133, 739–749.
128.
ShafeiMA, HarrisM, ConwayME (2017) Divergent metabolic regulation of autophagy and mTORC1-early events in Alzheimer’s disease?Front Aging Neurosci9, 173.
129.
JouvetP, RustinP, TaylorDL, PocockJM, Felderhoff-MueserU, MazarakisND, SarrafC, JoashiU, KozmaM, GreenwoodK, EdwardsAD, MehmetH (2000) Branched chain amino acids induce apoptosis in neural cells without mitochondrial membrane depolarization or cytochrome c release: Implications for neurological impairment associated with maple syrup urine disease. Mol Biol Cell11, 1919–1932.
130.
AmaralAU, LeipnitzG, FernandesCG, SeminottiB, SchuckPF, WajnerM (2010) Alpha-ketoisocaproic acid and leucine provoke mitochondrial bioenergetic dysfunction in rat brain. Brain Res1324, 75–84.
131.
BridiR, BraunCA, ZorziGK, WannmacherCM, WajnerM, LissiEG, Dutra-FilhoCS (2005) alpha-keto acids accumulating in maple syrup urine disease stimulate lipid peroxidation and reduce antioxidant defences in cerebral cortex from young rats. Metab Brain Dis20, 155–167.
132.
FunchalC, LatiniA, Jacques-SilvaMC, Dos SantosAQ, BuzinL, GottfriedC, WajnerM, Pessoa-PureurR (2006) Morphological alterations and induction of oxidative stress in glial cells caused by the branched-chain alpha-keto acids accumulating in maple syrup urine disease. Neurochem Int49, 640–650.
133.
GriffinJW, BradshawPC (2017) Amino acid catabolism in Alzheimer’s disease brain, Friend or foe?Oxid Med Cell Longev2017, 5472792.
